Last update 01 Nov 2024

TSD Japan, Inc.

Private Company|
2005|
Osaka-fu, Japan
|
www.tsd-japan.co.jp

Overview

Tags

Urogenital Diseases
Neoplasms
Immune System Diseases
Oncolytic virus
Fusion protein

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Hemic and Lymphatic Diseases1
Immune System Diseases1
Top 5 Drug TypeCount
Oncolytic virus1
Fusion protein1
Top 5 TargetCount
IL2RA(Interleukin-2 receptor alpha chain)1

Related

2
Drugs associated with TSD Japan, Inc.
Denileukin Diftitox
Target
IL2RA
Mechanism
IL2RA agonists
Active Org.
Northwestern UniversityNorthwestern University [+5]
Originator Org.
Ligand Pharmaceuticals, Inc.Ligand Pharmaceuticals, Inc.
Active Indication
Cutaneous T-cell lymphoma refractory [+5]
Inactive Indication
Alopecia [+15]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date05 Feb 1999
GEN-0101
Target-
Mechanism
Immunostimulants
Active Org.
Osaka UniversityOsaka University [+2]
Originator Org.
GenomIdea, Inc.
Active Indication
Melanoma [+2]
Inactive Indication
Castration-Resistant Prostatic Cancer
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with TSD Japan, Inc.
Login to view more data
0 Patents (Medical) associated with TSD Japan, Inc.
Login to view more data
1
Literatures (Medical) associated with TSD Japan, Inc.
Pharm Tech Japan
The drama to new medication: FK506
100 Deals associated with TSD Japan, Inc.
Login to view more data
100 Translational Medicine associated with TSD Japan, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
1
Approved
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Denileukin Diftitox
 ( IL2RA )		Peripheral T-Cell Lymphoma
More
Approved
GEN-0101
Melanoma
More
Phase 2
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free